Closing Soon
Drug for Rosacea, sponsored by Cutanea Life Sciences, Inc.
Get in touch This trial recruits from October 2015 for 104 weeks
TKL Research, Inc.
Phone: 201-587-0500
Inclusion Criteria
Age: From 18 Years To N/A
Gender: Both
Inclusion Criteria
Healthy, male and nonpregnant female subjects, 18 years of age or older.
A diagnosis of severe papulopustular rosacea using the Investigator Global Assessment grading scale at baseline
Subjects with the presence of telangiectasia at Baseline
Subjects with the presence of facial erythema associated with their rosacea at Baseline
Exclusion Criteria
Subjects with steroid rosacea or subtype 3 (phymatous rosacea).
Subjects with nodular rosacea
Standard exclusion criteria.
Exclusion Criteria
NCT02576847
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel